REGN
Regeneron Pharmaceuticals, Inc.
Stock
$735.20+0.39 (+0.05%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.5B | $14.3B | $14.2B | $13.1B | $12.2B | $16.1B | $8.5B | $6.6B | $5.1B | $5.9B | $4.9B | $4.1B | $2.8B | $2.1B | $1.4B | $446M | $459M | $379M | $238M |
| Cost of revenue | — | — | — | — | — | — | — | $403M | $238M | $203M | $195M | $242M | $129M | $118M | $84M | $4.2M | $2.1M | $1.7M | $923K |
| Gross profit | — | — | — | — | — | — | — | $6.2B | $4.9B | $5.7B | $4.7B | $3.9B | $2.7B | $2.0B | $1.3B | $442M | $457M | $378M | $238M |
| R&D | $6.3B | $5.9B | $5.1B | $4.4B | $3.6B | $2.9B | $2.6B | $2.5B | $1.5B | $2.1B | $2.1B | $1.6B | $1.3B | $860M | $626M | $530M | $489M | $399M | $275M |
| SG&A | $2.7B | $2.7B | $3.0B | $2.6B | $2.1B | $1.8B | $1.3B | $1.3B | $1.1B | $1.3B | $1.2B | $839M | $519M | $346M | $211M | $117M | $65M | $53M | $49M |
| Other operating expenses | — | — | — | — | — | — | — | $153M | — | $195M | $105M | $151M | $76M | $37M | — | — | — | — | — |
| Operating income | $3.8B | $3.6B | $4.0B | $4.0B | $4.7B | $8.9B | $3.6B | $2.2B | $2.5B | $2.1B | $1.3B | $1.3B | $824M | $743M | $458M | −$205M | −$97M | −$74M | −$86M |
| Non-operating income | $1.3B | $1.7B | $789M | $152M | $120M | $379M | $234M | $219M | $19M | −$1.1M | −$900K | −$27M | −$63M | −$47M | −$43M | −$18M | −$7.0M | $2.2M | $9.5M |
| Pretax income | $5.2B | $5.2B | $4.8B | $4.2B | $4.9B | $9.3B | $3.8B | $2.4B | $2.6B | $2.1B | $1.3B | $1.2B | $761M | $696M | $414M | −$223M | −$104M | −$72M | −$77M |
| Taxes | $837M | $726M | $367M | $246M | $520M | $1.3B | $297M | $313M | $109M | $880M | $434M | $589M | $423M | $283M | −$336M | −$1.1M | $0 | −$4.1M | $2.4M |
| Net income | $4.3B | $4.5B | $4.4B | $4.0B | $4.3B | $8.1B | $3.5B | $2.1B | $2.4B | $1.2B | $896M | $636M | $338M | $414M | $750M | −$222M | −$104M | −$68M | −$79M |
| Diluted EPS | $40.46 | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 | $5.52 | $2.98 | $3.72 | $6.75 | −$2.45 | −$1.26 | −$0.85 | — |
| Diluted shares | — | 108.6M | 115.1M | 113.7M | 113.5M | 112.2M | 115.1M | 114.6M | 114.8M | 115.9M | 116.3M | 115.2M | 113.4M | 111.3M | 115.4M | 90.6M | 82.9M | — | — |
| Revenue growth | — | +1.0% | +8.3% | +7.8% | −24.3% | +89.1% | +29.6% | +27.4% | −12.4% | +20.8% | +18.4% | +45.5% | +34.0% | +52.7% | +209.2% | −2.9% | +21.0% | +59.1% | — |
| Gross margin | — | — | — | — | — | — | — | 93.9% | 95.4% | 96.6% | 96.0% | 94.1% | 95.4% | 94.4% | 93.9% | 99.1% | 99.5% | 99.6% | 99.6% |
| Operating margin | 24.7% | 24.9% | 28.1% | 30.9% | 38.9% | 55.7% | 42.1% | 33.7% | 49.3% | 35.4% | 27.4% | 30.5% | 29.2% | 35.3% | 33.2% | −46.0% | −21.2% | −19.5% | −36.2% |
| Net margin | 27.9% | 31.4% | 31.1% | 30.1% | 35.6% | 50.2% | 41.3% | 32.3% | 47.5% | 20.4% | 18.4% | 15.5% | 12.0% | 19.7% | 54.4% | −49.7% | −22.8% | −17.9% | −33.2% |